[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100472647":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":25,"centralContacts":29,"locations":34,"responsibleParty":60,"collaborators":62,"id":70,"slug":71,"hasResults":72,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":18,"eligibilityCriteria":76,"healthyVolunteers":77,"sex":78,"minAge":79,"maxAge":18,"enrollmentInfo":80,"targetDuration":18,"studyType":83,"phases":84,"briefSummary":86,"conditions":87,"keywords":18,"overallStatus":36,"whyStopped":18,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":99},{"fullName":5,"class":6},"Washington University School of Medicine","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Patients: ChromSeq","EXPERIMENTAL","ChromoSeq will be performed on bone marrow or peripheral blood DNA from consented patients in parallel with the standard of care cytogenetics, FISH, and the MyeloSeq gene panel obtained from that sample, in a CLIA licensed environment using CLIA-compliant ChromoSeq procedures.",[13],"Device: ChromoSeq",{"label":15,"type":16,"description":17,"interventionNames":18},"Stakeholders (Treating Physicians)","NO_INTERVENTION","Stakeholders (treating physicians) will complete surveys\u002Fquestionnaires",null,[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":18},"DEVICE","ChromoSeq","Novel, streamlined whole genome sequencing approach",[9],[26],{"name":27,"affiliation":5,"role":28},"Meagan A Jacoby, M.D., Ph.D.","PRINCIPAL_INVESTIGATOR",[30],{"name":27,"role":31,"phone":32,"phoneExt":18,"email":33},"CONTACT","314-362-9405","mjacoby@wustl.edu",[35],{"facility":5,"status":36,"city":37,"state":38,"zip":39,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"RECRUITING","St Louis","Missouri","63110","United States","US",{"type":43,"coordinates":44},"Point",[45,46],-90.19789,38.62727,{"lat":46,"lon":45},[49,50,51,54,56,58],{"name":27,"role":31,"phone":32,"phoneExt":18,"email":33},{"name":27,"role":28,"phone":18,"phoneExt":18,"email":18},{"name":52,"role":53,"phone":18,"phoneExt":18,"email":18},"Matthew J Walter, M.D.","SUB_INVESTIGATOR",{"name":55,"role":53,"phone":18,"phoneExt":18,"email":18},"David H Spencer, M.D., Ph.D.",{"name":57,"role":53,"phone":18,"phoneExt":18,"email":18},"Mary C Politi, Ph.D.",{"name":59,"role":53,"phone":18,"phoneExt":18,"email":18},"Matthew Schuelke",{"type":61,"investigatorFullName":18,"investigatorTitle":18,"investigatorAffiliation":18,"oldNameTitle":18,"oldOrganization":18},"SPONSOR",[63,65,67],{"name":64,"class":6},"American Society of Hematology",{"name":66,"class":6},"Edward P. Evans Foundation",{"name":68,"class":69},"National Cancer Institute (NCI)","NIH","100472647","whole-genome-sequencing-chromoseq-as-an-adjunct-to-conventional-genomic-profiling-in-mds-100472647",false,"NCT05434598","Whole Genome Sequencing (ChromoSeq) as an Adjunct to Conventional Genomic Profiling in MDS","A Prospective Study of Whole Genome Sequencing (ChromoSeq) as an Adjunct to Conventional Genomic Profiling in MDS","Inclusion Criteria Patient:\n\n* Diagnosis of MDS, or a clinical suspicion for a new diagnosis of MDS, for whom routine diagnostic testing is requested or planned to be requested.\n* Seen in the outpatient setting.\n* Not been previously treated with disease-modifying therapy (such as lenalidomide or hypomethylating agents).\n\nNote: Patients who have received transfusional support, erythropoietin-stimulating agents, growth factor support, or luspatercept are eligible.\n\nAt least 18 years of age.\n\n-Able to understand and willing to sign an IRB approved written informed consent document.\n\nInclusion Criteria Physician:\n\n* Treating physician at Washington University School of Medicine who directs therapy for individuals with hematologic malignancies.\n* Able and willing to complete standardized questionnaires about stakeholder perceptions of ChromoSeq during the ChromoSeq implementation process. (Written documentation of informed consent is not required.)\n\nExclusion Criteria Patient:\n\n-Younger than 18 years of age\n\nExclusion Criteria Physician\n\n-Does not treat patients at Washington University School of Medicine",true,"ALL","18 Years",{"count":81,"type":82},60,"ESTIMATED","INTERVENTIONAL",[85],"NA","This is a single institution, prospective study of the whole genome sequencing assay, ChromoSeq. Using prospectively collected patient data, coupled with physician surveys, the investigators seek to determine the feasibility of implementing ChromoSeq in addition to standard genomic testing, for patients with the diagnosis of myelodysplastic syndrome (MDS).",[88,89],"Whole Genome Sequencing","Myelodysplastic Syndromes","2025-12-05",{"date":92,"type":93},"2025-12-11","ACTUAL",{"date":95,"type":93},"2022-07-27",{"date":97,"type":82},"2027-08-31",{"name":5,"class":6},1]